Regulators of apoptosis in human breast cancer

Clinical Biochemistry

Volumn 32, Issue 5, 1999, Pages 321-326

  Eissa, Sanaa ^a   Labib, Randa ^a   Khalifa, Ali ^a   Swelam, Nahed ^a   Khalil, Fawzia ^a   El Shenawy, Abdel Megeid ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Bcl 2; ER; p53

Indexed keywords

DNA; ESTROGEN RECEPTOR; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; APOPTOSIS; ARTICLE; BENIGN TUMOR; BREAST CARCINOMA; BREAST FIBROADENOMA; CANCER GRADING; CANCER HORMONE THERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MOLECULAR GENETICS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; ANEUPLOIDY; APOPTOSIS; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; IMMUNOBLOTTING; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032860943     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(99)00025-9     Document Type: Article

References (32)

1. Yonish-Rouach E., Rensmitzki D., Lotem J., Sachs L., Kimchi A., Oren M. Wild type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature. 352:1991;345-347.
2. Lotem J., Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and defective myeloid leukemic cells. Growth Differ. 3:1993;41-47.
3. Silvestrini R., Veneroni S., Daidone M.G., et al. The bcl-2 Protein a prognostic indicator strongly related to p53 in lymph node-negative breast cancer patients . J Natl Cancer Inst. 86:1994;499-504.
4. Leek R.D., Kaklamanis L., Pezzella F., Gatter K.C., Harris A.L. bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br J Cancer. 69:1994;135-139.
5. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C.M. Down- Regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54:1994;2095-2097.
6. Duenas-Gonzalez A., Abad-Hernandez M., Gruz-Hernandez J., Gonzalez-Sarmiento R. Analysis of bcl-2 in sporadic breast carcinoma. Cancer. 80:1997;2101-2108.
7. Lu Q.L., Poulsom R., Wong L., Hanby A.M. bcl-2 expression in adult and embryonic non-haematopoietic tissues. J Pathol. 169:1993;431-437.
8. Johnston S.R.D., Salter J., Maclennan K.A., et al. Short term tamoxifen induces the cytoplasmic expression of c-erbB-2 and bcl-2 in ER-positive human primary breast cancer. Breast. 3:1992;166.
9. Eissa S., Khalifa A., Laban M., Elian A., Bolton W.E. Comparison of flow cytometric DNA content analysis in fresh and paraffin-embedded ovarian neoplasm a prospective study . Br J Cancer. 77:1998;421-425.
10. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Bioch. 72:1976;248-251.
11. Eissa S., Seada L. Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay comparison with Western blot and immunohistochemistry . Clin Chem. 44:1998;1423-1429.
12. Hawkes R. The dot immunobinding assay. Methods Enzymol. 121:1986;484-491.
13. nd ed. Cold Spring Harbor, Laboratory Press 1989; 18: 42-57.
14. Hockenbery D.M., Zutter M., Hickey W., Nahm M., Korsmmeyer S.J. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA. 88:1991;6961-6965.
15. Baer R. Bcl-2 breathes life into embryogenesis. Am J Pathol. 145:1994;7-10.
16. Fisher D.E. Apoptosis in cancer therapy crossing the threshold . Cell. 78:1994;539-542.
17. Kerr J.F.R., Winterford C.M., Harmon B.V. Apoptosis. Its significance in cancer and cellular indications. J Natl Cancer Inst. 86:1994;1286-1296.
18. Stewart B.W. Mechanisms of apoptosis integration of genetic, biochemical, and cancer therapy . Cancer. 73:1994;2013-2026.
19. Gee J.M.W., Robertson J.F.R., Ellis I.O., et al. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 59:1994;619-628.
20. Johnston S.R.D., MacLennan K.A., Sacks N.P.M., Salter J., Smith I.E., Dowsett M. Modulation of bcl-2 and ki-67 expression in estrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer. 11:1994;1662-1669.
21. Hellemans P., Van Dam P.A., Weyler J., Van Osterom A.T., Buytaert P., Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 72:1995;354-360.
22. Baba M., Hideshima T., Shinohara T., Yamashital J.I., Shirakusa T. Immunohistochemical analysis of bcl-2 and p53 protein in breast carcinoma. Int J Oncol. 8:1996;355-358.
23. Charpin C., Andrac L., Vacheret H., et al. Multiparametic evaluation (SAMBA) of growth fraction (monoclonal ki67) in breast carcinoma a correlation of immunodetection in tissue sections and morphological data and estrogen and progesterone receptor immunocytochemical assays . Cancer Res. 48:1988;4368-4374.
24. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA. 89:1992;4495-4499.
25. Hockenbery D., Nunez G., Millima C., Schreiber R.D., Korsmeyer S.J. bcl-2 is an inter mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
26. Silvestrini R., Veneroni S., Daidone M.G., Benini E., Boracchi P., Mezzetti M. The bcl-2 protein a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 86:1994;499-504.
27. Gorczyca W., Markiewski M., Kram A., Tuziak T., Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas their correlation with ki-67 growth fraction . Virchows Arch. 426:1995;229-233.
28. Hurlimann J., Larrinaga B., Vala D.L. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch. 426:1995;163-168.
29. Doglioni C., dei-Tos A.P., Laurino I., Chiarelli C., Barbareschi M., Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to estrogen receptor status. Virchows Arch. 424:1994;47-51.
30. Miyashita T., Krajweski S., Krajewska M., Wang G.H., Lin H.K., Liebermann D.A. Tumor suppressor p53 is a regulator of bcl-2 and bax expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
31. Fisher T.C., Milner A.E., Gregory C.D., et al. bcl-2 modulation of apoptosis induced by anticancer drugs resistance pathway . Cancer Res. 53:1993;3321-3326.
32. Sentmann C.L., Shutter J.R., Hockenbery D., Kanagawa O., Korsmeyer S.J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67:1991;879-888.